Welcome to our dedicated page for TNF Pharmaceuticals SEC filings (Ticker: TNFA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNFA SEC filings page on Stock Titan provides access to the regulatory history of TNF Pharmaceuticals, Inc., the company that later became Q/C Technologies, Inc. and now trades on Nasdaq under the ticker QCLS. These filings document key corporate events, financing transactions and the formal name and ticker symbol change that marked the company’s shift from a clinical stage biopharmaceutical focus toward quantum-class photonic computing and blockchain infrastructure.
Among the notable documents is an 8-K filed on September 26, 2025, which reports the filing of a Certificate of Amendment to change the corporate name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc. and confirms that the company’s common stock ceased trading under TNFA and began trading under QCLS on the Nasdaq Stock Market. Other 8-K and 8-K/A filings describe a Securities Purchase Agreement for a private placement of Series H convertible preferred stock and warrants, the creation of Series I convertible preferred stock in connection with the acquisition of LPU Holdings LLC, and amendments to existing Series F and Series F-1 preferred stock designations.
Filings also include a Form 12b-25 (NT 10-Q), in which the company explains that it was unable to file its Quarterly Report on Form 10-Q for the six months ended June 30, 2025, within the prescribed time period without unreasonable effort or expense and anticipated filing within the allowed extension period. Together, these documents give insight into the company’s capital structure, preferred stock terms, acquisition agreements, licensing arrangements with LightSolver Ltd., and steps taken to manage its SEC reporting obligations.
On Stock Titan, users can review these TNFA filings alongside AI-powered summaries designed to clarify complex sections of 8-Ks, preferred stock designations and related agreements. Real-time updates from EDGAR ensure that new or amended filings tied to the historical TNFA entity and its successor Q/C Technologies appear promptly. Investors can also use the platform to track ownership and capital structure changes associated with preferred stock and warrants, and to connect the formal regulatory record with the company’s strategic pivot into quantum-class computing and blockchain infrastructure.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.
Q/C Technologies, Inc. reported that its Audit Committee dismissed Stephano Slack LLC as its independent registered public accounting firm on March 9, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor for the year ended December 31, 2025.
The prior auditor’s reports for 2023 and 2024 contained a going concern paragraph noting net loss and negative operating cash flows for 2024 that raised substantial doubt about the Company’s ability to continue as a going concern, with no related adjustments recorded. The Company states there were no disagreements or reportable events with Stephano Slack, and it has obtained a letter from the former auditor addressed to the SEC agreeing with these disclosures.
Q/C Technologies, Inc. reported that its Audit Committee dismissed Stephano Slack LLC as its independent registered public accounting firm on March 9, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor for the year ended December 31, 2025.
The prior auditor’s reports for 2023 and 2024 contained a going concern paragraph noting net loss and negative operating cash flows for 2024 that raised substantial doubt about the Company’s ability to continue as a going concern, with no related adjustments recorded. The Company states there were no disagreements or reportable events with Stephano Slack, and it has obtained a letter from the former auditor addressed to the SEC agreeing with these disclosures.
Q/C Technologies, Inc. has filed a shelf registration statement on Form S-3 to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
The company has shifted its strategy from developing Isomyosamine and Supera-CBD therapeutics to building energy‑efficient blockchain and cryptocurrency infrastructure using laser-based computing under an exclusive global license with LightSolver. The filing notes going concern risks, potential future equity dilution, Nasdaq listing compliance risks, and a high level of investment risk.
Q/C Technologies, Inc. has filed a shelf registration statement on Form S-3 to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
The company has shifted its strategy from developing Isomyosamine and Supera-CBD therapeutics to building energy‑efficient blockchain and cryptocurrency infrastructure using laser-based computing under an exclusive global license with LightSolver. The filing notes going concern risks, potential future equity dilution, Nasdaq listing compliance risks, and a high level of investment risk.
Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.
She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.
Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.
She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.